Recently, pleiotropic effects of glucagon-like peptide-1 (GLP-1), an incretin, have received attention not only for the benefit of GLP-1 analogues in management of diabetes9,10 but also for possible involvement in etiologies of various diseases including hepatic steatosis, renal failure and inflammatory bowel diseases11–13. The gene discussed is GLP1R; the disease is kidney failure.